Syncona
Limited
Publication of 2024 Annual
Report and Notice of Annual General Meeting
3 July 2024
Syncona Ltd, a leading life science
investor focused on creating, building and scaling a portfolio of
global leaders in life science, today announces that it has
published its Annual Report and Accounts for the year ended 31
March 2024 ("2024 Annual Report") and its Notice of the Annual
General Meeting 2024.
In compliance with Listing Rule 9.6.1, these
documents will today be filed with the National Storage Mechanism
and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The Notice of the Annual General Meeting 2024 is
available on Syncona's website at
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.
The 2024 Annual Report is available on Syncona's website at
https://www.synconaltd.com/investors/results-and-presentations/.
Printed copies of these documents are also being posted to
shareholders where requested.
Syncona's Annual General Meeting
will be held at 1.00 p.m. on 6 August 2024 at the offices of Citco
Fund Services (Guernsey) Limited, Frances House, Sir William Place,
St. Peter Port, Guernsey, GY1 1GX.
Shareholders are
encouraged to ensure that their votes are counted at the 2024
Annual General Meeting by appointing the chair of the 2024 Annual
General Meeting as their proxy in line with the procedures set out
in the Notice of Annual General Meeting.
Enquiries
Syncona Limited
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 20 3981
7940
FTI Consulting
Ben Atwell / Tim Stamper
Tel: +44 (0) 20 3727 1000
About
Syncona:
Syncona's purpose is to invest to extend and enhance
human life. We do this by creating, building and scaling companies
to deliver transformational treatments to patients in areas of high
unmet need.
We aim to build and maintain a
diversified portfolio of 20-25 globally leading life science
businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on
developing treatments that deliver patient impact by working in
close partnership with world-class academic founders and
experienced management teams. Our balance sheet underpins our
strategy, enabling us to take a long-term view as we look to
improve the lives of patients with no or poor treatment options,
build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.